The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ostroumova O.D.

Kafedra fakul'tetskoĭ terapii i professional'nykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta im. A.I. Evdokimova, Moskva

Shakhova E.Yu.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia, Moscow, Russia

Kochetkov A.I.

FSBEI of Higher Education 'N.I. Pirogov Russian National Research Medical University' of the Ministry of Health of the Russia — Russian Clinical and Research Center of Gerontology, Moscow, Russia

Drug-induced constipation

Authors:

Ostroumova O.D., Shakhova E.Yu., Kochetkov A.I.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2020;9(1): 20‑31

DOI: 10.17116/dokgastro2020901120

Read: 19845 times

Download PDF (RU)
Contact the author
Table of contents

DRUG-INDUCED CONSTIPATION
DRUG-INDUCED CONSTIPATION

To cite this article:

Ostroumova OD, Shakhova EYu, Kochetkov AI. Drug-induced constipation. Russian Journal of Evidence-Based Gastroenterology. 2020;9(1):20‑31. (In Russ.)
https://doi.org/10.17116/dokgastro2020901120

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Objective is to highlight the prevalence, pathogenesis, risk factors, diagnosis, treatment, and prevention of drug-induced constipation. Main statements. Constipation is one of the most common adverse side effects of various medicines. Usually, it develops with the use of opioid analgesics, chemotherapeutic drugs, non-steroidal anti-inflammatory drugs, anticholinergic drugs, antihypertensive, antiarrhythmic drugs, as well as in case of abuse of laxatives and fibers. Risk factors for the development of drug-induced constipation include: the patient’s primary or secondary constipation due to other reasons, older age, female gender, simultaneous administration of ≥2 drugs that can cause constipation, duration of therapy with drugs that can cause constipation (for opioid-induced constipation), dehydration, colonic hypomotility, poor/unbalanced nutrition, pregnancy. A method of preventing drug-induced constipation is a tapering, withdrawal, or replacement of the drug that caused this side effect. It is necessary to recommend for the patient a lifestyle modification, including dietary changes, an increase in fluid intake and physical activity. If nonpharmacological measures are not effective, drug therapy (laxatives) should be advised. Conclusion. It is necessary to raise the awareness of practitioners of various specialties about risk factors for constipation development, primarily to ensure adequate prevention, early diagnosis, and effective treatment.

Keywords:

constipation
drug-induced constipation
opioid-induced constipation
adverse drug reactions

Authors:

Ostroumova O.D.

Kafedra fakul'tetskoĭ terapii i professional'nykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta im. A.I. Evdokimova, Moskva

Shakhova E.Yu.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia, Moscow, Russia

Kochetkov A.I.

FSBEI of Higher Education 'N.I. Pirogov Russian National Research Medical University' of the Ministry of Health of the Russia — Russian Clinical and Research Center of Gerontology, Moscow, Russia

Close metadata

References:

  1. Fortan P, Hawkey C. Drug-induced gastrointestinal disorders. Medicine. 2007;35(4):210-215. https://doi.org/10.1016/j.mpmed.2007.01.012
  2. Price AB. Pathology of drug-associated gastrointestinal disease. British Journal of Clinical Pharmacology. 2003;56(5):477-482. https://doi.org/10.1046/j.1365-2125.2003.01980.x
  3. Ghahremani GG. Gastrointestinal complications of drug therapy. Abdominal Imaging. 1999;24(1):1-2. https://doi.org/10.1007/s002619900430
  4. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-148. https://doi.org/10.1056/NEJMoa1209096
  5. Kadcyla. South San Francisco. CA: Genentech Inc.; 2013.
  6. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson D, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YCh, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. The Lancet. 2011;378(9807):1931-1939. https://doi.org/10.1016/S0140-6736(11)61613-9
  7. Avastin. South San Francisco, CA: Genentech Inc.; 2015.
  8. Wirth M, Tyrrell C, Delaere K, Sánchez-Chapado M, Ramon J, Wallace MA, Hetherington J, Pina F, Heyns CF, Navani S. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis. 2006;10:87-93. https://doi.org/10.1038/sj.pcan.4500916
  9. Tyrrell CJ, Iversen P, Tammela T, Anderson J, Bjork T, Kaisary AV, Morris T. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. BJU Int. 2006;98(3):563-572. https://doi.org/10.1111/j.1464-410X.2006.06275.x
  10. See WA, Tyrrell CJ; CASODEX Early Prostate Cancer Trialists’ Group. The addition of bicalutamide 150 mg to radiotherapy sig-nificantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol. 2006;132(1):7-16. https://doi.org/10.1007/s00432-006-0132-6
  11. Colemana RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart MA. Randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42(7):882-887. https://doi.org/10.1016/j.ejca.2005.12.011
  12. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281. https://doi.org/10.1056/NEJMoa066838
  13. Bourne MH, Rosenthal NR, Xiang J, Jordan D, Kamin M. Tramadol/acetaminophen tablets in the treatment of postsurgical orthopedic pain. Am J Orthop. 2005;34(12):592-597.
  14. Smith AB, Ravikumar TS, Kamin M, Jordan D, Xiang J, Rosenthal N; CAPSS-115 Study Group. Combination tramadol plus acetaminophen for postsurgical pain. Am J Surg. 2004;187(4):521-527. https://doi.org/10.1016/j.amjsurg.2003.12.038
  15. Rodriguez RF, Castillo JM, Del Pilar Castillo M, Nuñez PD, Rodriguez MF, Restrepo JM, Rodriguez JM, Ortiz Y, Angel AM. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day prospective, double-blind, randomized, parallel-group study. Clin Ther. 2007;29(4):581-587. https://doi.org/10.1016/j.clinthera.2007.04.004
  16. Allan L, Richarz U, Simpson, K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine. 2005;30(22):2484-2490. https://doi.org/10.1097/01.brs.0000186860.23078.a8
  17. van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin. 2003;19(6):457-469. https://doi.org/10.1185/030079903125002045
  18. Marco CA, Plewa MC, Buderer N, Black C, Roberts A. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial. Acad Emerg Med. 2005;12(4):282-288. https://doi.org/10.1197/j.aem.2004.12.005
  19. Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007;29(5):874-888. https://doi.org/10.1016/j.clinthera.2007.05.016
  20. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290-1297. https://doi.org/10.1056/NEJM200011023431802
  21. Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled: release oxycodone HCI in moderate to severe nonmalignant pain. Curr Med Res Opin. 2006;22(8):1503-1514. https://doi.org/10.1185/030079906X115603
  22. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropsion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47(2):174-180. https://doi.org/10.1177/070674370204700208
  23. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001;57(9):1580-1588. https://doi.org/10.1212/WNL.57.9.1583
  24. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36(6): 383-390. https://doi.org/10.1016/S0022-3956(02)00060-2
  25. Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, Bump R; Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007;100(2):337-345. https://doi.org/10.1111/j.1464-410X.2007.06980.x
  26. Beasley CMJ, Holman SL, Potvin JH. Fluoxetine Compared with Imipramine in the Treatment of Inpatient Depression A Multicenter Trial. J Ann Clin Psychiatry. 1993;5(3):199-207.
  27. Chouinard G, Saxena B, Bélanger MC, Ravindran A, Bakish D, Beauclair L, Morris P, Vasavan Nair NP, Manchanda R, Reesal R, Remick R, O’Neill MC. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord. 1999;54(1-2):39-48. https://doi.org/10.1016/s0165-0327(98)00188-8
  28. Versiani M, Amrein R, Stabl M. Moclobemide and imipramine in chronic depression (dysthymia): an international double- blind, placebo-controlled trial. J Int Clin Prychopharmacol. 1997;12(4):183-193. https://doi.org/10.1097/00004850-199707000-00001
  29. Cohn JB, Crowder JE, Wilcox CS, Ryan PJ. A placebo- and imipramine-controlled study of paroxetine. Psychopharmacology Bulletin. 1990;26(2):185-189.
  30. Bielski RJ, Bose A, Chang CC. A Double-Blind Comparison of Escitalopram and Paroxetine in the Long-Term Treatment of Generalized Anxiety Disorder. J Ann Clin Psychiatry. 2005;17(2):65-69. https://doi.org/10.1080/10401230590932326
  31. Thase ME, Shelton RC, Khan A. Treatment with Venlafaxine Extended Release After SSRI Nonresponse or Intolerance: A Randomized Comparison of Standard- and Higher-dosing Strategies. Journal of Clinical Psychopharmacology. 2006;26(3):250-258. https://doi.org/10.1097/01.jcp.0000219922.19305.08
  32. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. The Journal of Clinical Psychiatry. 2007;68(6):843-853. https://doi.org/10.4088/jcp.v68n0604
  33. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R. Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression: Results of 2 Randomized, Placebo-Controlled Studies. J Clin Psychopharmacol. 2008;28(1):13-20. https://doi.org/10.1097/jcp.0b013e3181618eb4
  34. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28(1):5-12. https://doi.org/10.1097/jcp.0b013e3181602fd4
  35. Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006;21(6):393-398. https://doi.org/10.1002/hup.781
  36. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ; Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. https://doi.org/10.1016/S0006-3223(00)01026-X
  37. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, Bossie CA, Davidson M, Burtea V, Zhu Y, Trivedi JK. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006;85(1-3):254-265. https://doi.org/10.1016/j.schres.2006.03.027
  38. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-609. https://doi.org/10.1097/01.jcp.0000248603.76231.b7
  39. Herndon CM, Jackson KC, Hallin PA. Management of opioid- induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy. 2002;22(2):240-250. https://doi.org/10.1592/phco.22.3.240.33552
  40. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. Southern Medical Journal. 2004;97(2):129-134. https://doi.org/10.1097/01.SMJ.0000109215.54052.D8
  41. Donatelle EP. Constipation: pathophysiology and treatment. Am Fam Physician. 1990;42(5):1335-1342.
  42. Talley NJ, Jones M, Nuyts G, Dubois D. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol. 2003;98(5):1107-1111. https://doi.org/10.1111/j.1572-0241.2003.07465.x
  43. Opie LH. Calcium channel antagonists. Part III: use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications. Cardiovasc Drugs Ther. 1988;1(6):625-656. https://doi.org/10.1007/bf02125750
  44. Opie LH. Calcium channel antagonists. Part IV: side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther. 1988;2(2):177-189. https://doi.org/10.1007/bf00051233
  45. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996;15(2):91-106. https://doi.org/10.2165/00002018-199615020-00002
  46. Findling R, Frishman W, Javed MT, Heffer S, Brandt L. Calcium channel blockers and the gastrointestinal tract. Am J Ther. 1996;3(5):383-408. https://doi.org/10.1097/00045391-199605000-00009
  47. Chang JY, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Risk factors for chronic constipation and a possible role of analgesics. Neurogastroenterol Motil. 2007;19(11):905-911. https://doi.org/10.1111/j.1365-2982.2007.00974.x
  48. Ivashkin VT, Maev IV, Sheptulin AA, Trukhmanov AS, Poluektova EA, Baranskaya EK, Shifrin OS, Lapina TL, Osipenko MF, Simanenkov VI, Khlynov IB. Clinical recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of adult patients with chronic constipation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(3):75-83. (In Russ.).
  49. Truven Health Analytics Inc Micromedex solutions 2018. Accessed December 08, 2019. https://www.micromedexsolutions.com/micromedex2/librarian
  50. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T; Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37(10):1298-1303. https://doi.org/10.1086/379015
  51. Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M; Japanese Solifenacin Study Group. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100(3):579-587. https://doi.org/10.1111/j.1464-410X.2007.07031.x
  52. Goldberg RM, Loprinzi CL, O’Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose AM, Rowland KM Jr, Burnham NL. Transdermal clonidine for ameliorating tamoxifen- induced hot flashes. J Clin Oncol. 1994;12(1):155-158. https://doi.org/10.1200/JCO.1994.12.1.155
  53. Distler A, Kirch W, Liith B. Antihypertensive effect of guanfacine: a double‐blind cross‐over trial compared with clonidine. B J C P. 1980;10(1):495-538. https://doi.org/10.1111/j.1365-2125.1980.tb04904.x
  54. Fosnes GS, Lydersen S, Farup PG. Constipation and diarrhoea — common adverse drug reactions? A cross sectional study in the general population. BMC Clin Pharmacol. 2011;11:2. https://doi.org/10.1186/1472-6904-11-2
  55. Roeckel A, Heidland A. Comparative studies of guanfacine and methyldopa. Br J Clin Pharmacol. 1980;10(1):55-59. https://doi.org/10.1111/j.1365-2125.1980.tb04905.x
  56. Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators J Hypertens. 1997;15(11):1337-1344. https://doi.org/10.1097/00004872-199715110-00019
  57. Cutler NR, Anders RJ, Jhee SS, Sramek JJ, Awan NA, Bultas J, Lahiri A, Woroszylska M. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol. 1995;75(16):1102-1106. https://doi.org/10.1016/S0002-9149(99)80738-3
  58. Chiou TJ, Wang TH, Chao TY, Lin SF, Tang JL, Chen TY, Chang MC, Hsueh EJ, Chen PM. Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Invest. 2007;25(3):140-147. https://doi.org/10.1080/07357900701208808
  59. Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, Delibasi S, Kyrtsonis MC, Anagnostopoulos N, Terpos E, Zikos P, Maniatis A, Dimopoulos MA; Greek Myeloma Study Group. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol. 2007;18(8):1369-1375. https://doi.org/10.1093/annonc/mdm178
  60. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the Glucose-lowering effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29(1):74-83. https://doi.org/10.1016/j.clinthera.2007.01.003
  61. Spence JD, Huff MW, Heidenheim P, Viswanatha A, Munoz C, Lindsay R, Wolfe B, Mills D. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med. 1995;123(7):493-499. https://doi.org/10.7326/0003-4819-123-7-199510010-00003
  62. Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastates. Clin Cancer Res. 2001;7(3):478-485.
  63. Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift RA, Conde F, Von Teichert JM. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer. 2001;91(1):144-154. https://doi.org/10.1002/1097-0142(20010101)91:1%3C144::aid-cncr19%3E3.0.co;2-q
  64. Nulojix. Princeton, New Jersey: Bristol-Myers Squibb; 2014.
  65. Liguori L. Iron protein succinylate in the treatment of iron deficienct: controlled, double-blind, multicenter clinical trial on over 1,000 patients. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1993;31(3):103-123.
  66. Coplin M, Schuette S, Leichtmann G, Lashner B. Tolerability of iron: a comparison of bis-glycino iron II and ferrous sulfate. Clin Ther. 1991;13(5):606-612.
  67. Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001;96(3):803-811. https://doi.org/10.1016/S0002-9270(00)02419-9
  68. Sigsgaard T, Herrstedt J, Andersen LJ, Havsteen H, Langer SW, Kjaerbøl AG, Lund H, Kjaer M, Dombernowsky P. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer. 1999;80(3-4):412-418. https://doi.org/10.1038/sj.bjc.6690372
  69. Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018.
  70. Coyne KS, LoCasale RJ, Datto CJ, Sexton CC, Yeomans K, Tack J. The burden of opioid-induced constipation: discordance between patient and health care provider reports. J Manag Care Spec Pharm. 2016;22(3):236-245. https://doi.org/10.2147/CEOR.S61602
  71. Bharucha AE. Constipation. Best Pract Res Clin Gastroenterol. 2007;21(4):709-731. https://doi.org/10.1016/j.bpg.2007.07.001
  72. Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol Suppl. 2014;2(1):31-37. https://doi.org/10.1038/ajgsup.2014.7
  73. Szigethy E, Schwartz M, Drossman D. Narcotic bowel syndrome constipation in elderly patients. Curr Gastroenterol Rep. 2014;16(10):410. https://doi.org/10.1007/s11894-014-0410-4
  74. Siemens W, Gaertner J, Becker G. Advances in pharmacotherapy for opioid-induced constipation-a systematic review. Expert Opin Pharmacother. 2015;16(4):515-532. https://doi.org/10.1517/14656566.2015.995625
  75. Wald A. Constipation: pathophysiology and management. Curr Opin Gastroenterol. 2015;31(1):45-49. https://doi.org/10.1097/MOG.0000000000000137
  76. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60(2):209-218. https://doi.org/10.1136/gut.2010.227132
  77. Camilleri M. New treatment options for chronic constipation: mechanisms, efficacy, and safety. Can J Gastroenterol. 2011;l:29-35. https://doi.org/10.1155/2011/527583
  78. Seth P, Scholl L, Rudd RA, Bacon S. Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015—2016. Morb Mortal Wkly Rep. 2018;67(12):349-358. https://doi.org/10.15585/mmwr.mm6712a1
  79. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, Alexander GC. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annual Rev of Public Health. 2015;36:559-574. https://doi.org/10.1146/annurev-publhealth-031914-122957
  80. Murthy VH. Ending the opioid epidemic — a call to action. N Engl J Med. 2016;375(25):2413-2115. https://doi.org/10.1056/NEJMp1612578
  81. Markland AD, Palsson O, Goode PS, Burgio KL, Busby-Whitehead J, Whitehead WE. Association of low dietary intake of fiber and liquids with constipation: evidence from the National Health and Nutrition Examination Survey. Am J Gastroenterol. 2013;108(5):796-803. https://doi.org/10.1038/ajg.2013.73
  82. De Schryver AM, Keulemans YC, Peters HP, Akkermans LM, Smout AJ, De Vries WR, van Berge-Henegouwen GP. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation. Scand J Gastroenterol. 2005;40(4):422-429. https://doi.org/10.1080/00365520510011641
  83. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):58-68. https://doi.org/10.1016/S1470-2045(12)70040-2
  84. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine. 2005;30(22): 2484-2490. https://doi.org/10.1097/01.brs.0000186860.23078.a8
  85. Muller-Lissner S, Bassotti G, Coffin B, Drewes AM, Breivik H, Eisenberg E, Emmanuel A, Laroche F, Meissner W, Morlion B. Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline. Pain Med. 2017;18(10):1837-1863. https://doi.org/10.1093/pm/pnw255
  86. Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterol. 2019;156(1):218-226. https://doi.org/10.1053/j.gastro.2018.07.016
  87. Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371-383. https://doi.org/10.3111/13696990903430481
  88. Ueberall MA, Müller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non- constipated population of pain patients. J Int Med Res. 2011;39(1):41-50. https://doi.org/10.1177/147323001103900106
  89. Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, Webster LR. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16(12):2324-2337. https://doi.org/10.1111/pme.12937
  90. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol. 1999;34(9):870-877. https://doi.org/10.1080/003655299750025327
  91. Roque M, Bouras EP. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99(4): 750-759. https://doi.org/10.1111/j.1572-0241.2004.04114.x
  92. Locke GR, Pemberton JH, Phillips SE. AGA technical review on constipation. Gastroenterology. 2000;119(6):1766-1778. https://doi.org/10.1053/gast.2000.20392
  93. Johanson JF. Review of the treatment options for chronic constipation. Med Gen Med. 2007;9(2):25.
  94. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009;27(23):3842-3848. https://doi.org/10.1200/JCO.2008.19.6550
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.